Extraintestinal Manifestations and Intestinal Complications in Patients with Crohn's Disease: Associations with Some Clinico-Laboratory Findings, Immunological Markers and Therapy
暂无分享,去创建一个
[1] L. A. Troncon,et al. Extraintestinal manifestations of inflammatory bowel disease: Clinical aspects and pathogenesis. , 2018 .
[2] K. Mahtani,et al. Immunosuppression for management of Crohn's disease , 2016, The Lancet.
[3] A. Bitton,et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial , 2015, The Lancet.
[4] Hanan Khalil,et al. Crohn’s disease: a clinical update , 2015, Therapeutic advances in gastroenterology.
[5] H. Freeman. Natural history and long-term clinical course of Crohn's disease. , 2014, World journal of gastroenterology.
[6] M. Ciorba,et al. Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.
[7] J. Lewis. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.
[8] R. Burakoff,et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. , 2022, Rhode Island medical journal.
[9] Esther Jacobowitz Israel,et al. Shortcomings of the Inflammatory Bowel Disease Serology 7 Panel , 2010, Pediatrics.
[10] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[11] Malfertheiner,et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.
[12] T. Piche. Impact de la chirurgie gynécologique sur le développement du syndrome de l’intestin irritable et des douleurs abdominales , 2008 .
[13] E. Stange,et al. Extraintestinal manifestations and complications in inflammatory bowel diseases. , 2006, World journal of gastroenterology.
[14] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[15] A. Nakajima,et al. Intestinal Antiinflammatory Effects of Thiazolidenedione Peroxisome Proliferator‐Activated Receptor‐&ggr; Ligands on T Helper Type 1 Chemokine Regulation Include Nontranscriptional Control Mechanisms , 2005, Inflammatory bowel diseases.
[16] R. Fedorak. Is it time to re-classify Crohn's disease? , 2004, Best practice & research. Clinical gastroenterology.
[17] A. Peña,et al. Treatment of extraintestinal manifestations in inflammatory bowel disease , 2003, Current treatment options in gastroenterology.
[18] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[19] G. Hellers. Crohn's disease in Stockholm county 1955-1974. A study of epidemiology, results of surgical treatment and long-term prognosis. , 1979, Acta chirurgica Scandinavica. Supplementum.
[20] F. Bardachzi. Vergleichende Untersuchungen bei Magenkrankheiten mit besonderer Berücksichtigung der Methoden zur Prüfung der motorischen Magenfunktion , 1911 .